-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple myeloma (MM) is a hematological malignant tumor characterized by the proliferation of monoclonal plasma cells, accounting for about 10% of all hematological malignancies.
After 4-6 courses of treatment with high-dose melphalan-induced autologous stem cell transplantation (ASCT), it is recommended to collect peripheral blood stem cells
A retrospective examination of 57 patients with multiple myeloma who underwent autologous stem cell transplantation (ASCT) at the research institution
Receiver operating characteristic curve (ROC) analysis showed that the reduction rate of quantitative serum monoclonal protein (M protein) before ASCT and the difference between participating and not participating in free light chain (dFLC) at 30 days after ASCT were the largest predictions for all patients Values (area under the curve [AUC] are 0.
Receiver operating characteristic curve (ROC) analysis showed that the reduction rate of quantitative serum monoclonal protein (M protein) before ASCT and the difference between participating and not participating in free light chain (dFLC) at 30 days after ASCT were the largest predictions for all patients Values (area under the curve [AUC] are 0.
Figure 1: All patients' serum: M protein (a, e), absolute immunoglobulin (b, f), iFLC (c, g) and dFLC (d, h) progression-free survival curve analysis
Figure 1: All patients' serum: M protein (a, e), absolute immunoglobulin (b, f), iFLC (c, g) and dFLC (d, h) progression-free survival curve analysis
Figure 2: Kaplan-Meier estimated the 30-day serum (a) protein reduction rate after ASCT and the progression-free survival of all patients with dFLC (a, b) and patients who could not reach VGPR (c) (b, c)
Figure 2: Kaplan-Meier estimated the 30-day serum (a) protein reduction rate after ASCT and the progression-free survival of all patients with dFLC (a, b) and patients who could not reach VGPR (c) (b, c)
Based on the cut-off values of tumor burden parameters based on the ROC curve, the progression-free survival (PFS) of the high serum M protein reduction (≥90%) group was significantly better than the low serum M protein reduction group (<90%) (2 years PFS 79.
Table: Univariate and multivariate analysis of PFS before and after ASCT (all patients, patients who did not achieve VGPR before ASCT)
Table: Univariate and multivariate analysis of PFS before and after ASCT (all patients, patients who did not achieve VGPR before ASCT)
Multivariate analysis determined that the decrease of serum M protein was an independent predictor of PFS before ASCT (hazard ratio [HR] 0.
This study analyzed the tumor burden parameters of MM before and after ASCT to determine its relationship with patient prognosis, and showed that PFS is superior to patients whose serum m protein reduction rate is ≥90%, that is, those patients who reach VGPR before ASCT
Early dFLC after transplantation can predict its prognosis
Original source:
Minakata D,Fujiwara SI,Murahashi R,et al.
Leave a message here
